Treat to target or "treat to clear" in inflammatory bowel diseases: one step further?
Fiche publication
Date publication
août 2020
Journal
Expert review of gastroenterology & hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Dal Buono A, Roda G, Argollo M, Zacharopoulou E, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
Inflammatory bowel diseases (IBD), are chronic and progressive diseases. Long-term complications are demolitive surgery and colon-rectal cancer. A "treat to target" strategy, in which the treatment aims to achieve objective outcomes, has already been introduced in the management of chronic conditions as rheumatic diseases. This approach is emerging as suitable for ulcerative colitis and Crohn's disease. Targets are pre-defined therapeutic goals demonstrated to prevent end-organ dysfunction . An optimization or switch of therapy is considered depending on the target's achievement, with regular monitoring.
Mots clés
histological healing, inflammatory bowel diseases, long-term outcomes, mucosal healing, remission, treat-to-target
Référence
Expert Rev Gastroenterol Hepatol. 2020 Aug 7;: